B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells

Logo poskytovatele
Logo poskytovatele

Varování

Publikace nespadá pod Fakultu sportovních studií, ale pod Středoevropský technologický institut. Oficiální stránka publikace je na webu muni.cz.
Autoři

ŠEDA Václav MRÁZ Marek

Rok publikování 2015
Druh Článek v odborném periodiku
Časopis / Zdroj European Journal of Haematology
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
www http://onlinelibrary.wiley.com/doi/10.1111/ejh.12427/pdf
Doi http://dx.doi.org/10.1111/ejh.12427
Obor Onkologie a hematologie
Klíčová slova LYN; B cell; B-cell receptor; Bruton tyrosine kinase; Ibrutinib; MiRNA; PI(3)K; Spleen tyrosine kinase; ZAP-70
Přiložené soubory
Popis The physiology of B cells is intimately connected with the function of their B-cell receptor (BCR). B-cell lymphomas frequently (dys)regulate BCR signalling and thus take advantage of this pre-existing pathway for B-cell proliferation and survival. This has recently been underscored by clinical trials demonstrating that small molecules (fosfamatinib, ibrutinib, idelalisib) inhibiting BCR-associated kinases (SYK, BTK, PI3K) have an encouraging clinical effect. Here we describe the current knowledge of the specific aspects of BCR signalling in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, chronic lymphocytic leukaemia (CLL) and normal B cells. Multiple factors can contribute to BCR pathway (dys)regulation in these malignancies and the activation of 'chronic' or 'tonic' BCR signalling. In lymphoma B cells, the balance of initiation, amplitude and duration of BCR activation can be influenced by a specific immunoglobulin structure, the expression and mutations of adaptor molecules (like GAB1, BLNK, GRB2, CARD11), the activity of kinases (like LYN, SYK, PI3K) or phosphatases (like SHIP-1, SHP-1 and PTEN) and levels of microRNAs. We also discuss the crosstalk of BCR with other signalling pathways (NF-KB, adhesion through integrins, migration and chemokine signalling) to emphasise that the 'BCR inhibitors' target multiple pathways interconnected with BCR, which might explain some of their clinical activity.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info